-- 根據週四提交給澳洲證券交易所的文件，Neurizon Therapeutics（ASX：NUZ）已獲得270萬澳元的確定性融資承諾，以彌補其近期完成的按比例不可放棄配股發行的資金缺口。此次配股發行目標為1,710萬澳元，已籌集約590萬澳元，剩餘約1,130萬澳元。 根據文件，該公司將以每股0.08澳元的價格發行3,320萬股新股，與現有股份享有同等權益。 文件顯示，交割日期定於4月20日，配股日期定於4月21日。 文件還指出，籌集的資金將用於推進其主要候選藥物NUZ-001的臨床開發和潛在商業化，以及滿足一般營運資金需求。 該公司股價在周四的交易中下跌了約7%。
Related Articles
Asia
Seatrium Concludes the Divestment of Tugboat Fleet
Seatrium (SGX:5E2) completed the divestment of a fleet of 17 tugboats, according to a Monday filing with the Singapore Exchange.The divestment is expected to deliver over SG$50 million in annualized cost savings.Shares of the specialized engineering solutions company were down over 2% in Monday trading.
$SGX:5E2
Asia
China Nuclear Engineering's Attributable Profit Slides 36% in 2025
China Nuclear Engineering's (SHA:601611) attributable profit fell 36% to 1.32 billion yuan in 2025 from 2.06 billion yuan in 2024, according to a Saturday filing with the Shanghai bourse.Earnings per share at the nuclear power company decreased 37% to 0.36 yuan from 0.57 yuan in the previous year.Operating revenue declined 10% year over year to 101.9 billion yuan from 113.5 billion yuan.Shares decreased 2% during the midday break on Monday.
$SHA:601611
Asia
Junzheng Energy & Chemical's Attributable Profit Rises 18% in 2025; Shares Rise 4%
Inner Mongolia Junzheng Energy & Chemical's (SHA:601216) attributable profit rose 18% to 3.32 billion yuan in 2025 from 2.80 billion yuan in 2024, according to a Saturday filing with the Shanghai bourse.Earnings per share at the chemical manufacturer increased to 0.3932 yuan from 0.3323 yuan in the previous year.Operating revenue stayed flat at 25.2 billion yuan.Shares increased 4% during the midday break on Monday.
$SHA:601216